GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance. 1w. GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American ... driven by strong performance across all ...

Spark’s Take on GB:GSK Stock According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform. GlaxoSmithKline’s stock is supported by strong financial performance and strategic initiatives ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma therapy approval.

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain ...

GSK is scheduled to report results for the first quarter on Wednesday. Here is what to know. SALES FORECAST: The British pharmaceutical giant is expected to report sales for the period of 7.42 ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

GSK (NYSE:GSK – Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, April 30th. Analysts expect GSK to post earnings of $1.06 per share and ...

GSK’s Price Performance, Valuation & Estimate Movement. GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.